Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,040 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $51.40, for a total value of $361,856.00. Following the transaction, the chief executive officer directly owned 36,680 shares of the company’s stock, valued at $1,885,352. The trade was a 16.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total transaction of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total value of $552,372.84.

Phibro Animal Health Price Performance

Shares of PAHC stock traded down $1.21 during trading hours on Wednesday, reaching $51.08. The company had a trading volume of 285,202 shares, compared to its average volume of 292,928. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The stock has a fifty day moving average of $41.97 and a 200-day moving average of $39.69. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 0.80 and a beta of 0.80. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is presently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the period. Millennium Management LLC boosted its position in shares of Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares during the period. Jane Street Group LLC grew its stake in shares of Phibro Animal Health by 65.3% in the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares in the last quarter. Yousif Capital Management LLC acquired a new stake in shares of Phibro Animal Health in the second quarter valued at $200,000. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Phibro Animal Health by 97.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock valued at $621,000 after buying an additional 11,999 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on PAHC shares. JPMorgan Chase & Co. lifted their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.